Screener
Denali Therapeutics Inc. DNLI Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
FAQ
- What is Denali Therapeutics Inc.'s retained earnings?
- Denali Therapeutics Inc. (DNLI) reported retained earnings of -$2.31B in Q2 2026.
- How has Denali Therapeutics Inc.'s retained earnings changed year-over-year?
- Denali Therapeutics Inc.'s retained earnings decreased by 28.5% year-over-year, from -$1.8B to -$2.31B.
- What is the long-term trend for Denali Therapeutics Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s retained earnings has grown at a 42.1% compound annual growth rate (CAGR), from -$354.42M to -$2.05B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Denali Therapeutics Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude